---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-25-009966"
form_type: "8-K"
ticker: "CVM"
cik: "0000725363"
company_name: "CEL SCI CORP"
filed_at: "2025-08-25T23:59:59+00:00"
generated_at: "2026-05-17T10:26:35.473890+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CEL-SCI files Breakthrough Medicine Designation with Saudi FDA for Multikine; signs MOU with Dallah Pharma

## Summary
- Breakthrough Medicine Designation application filed with SFDA by Dallah Pharma for Multikine.
- MOU signed with Dallah Pharma for commercialization; final partnership expected Q3 2025.
- SFDA response time ~60 days; if granted, Multikine available for patient access and reimbursement in Saudi Arabia.
- Dallah Healthcare serves over 3 million patients annually via network of hospitals and clinics.

## SEC filing metadata
- accession: 0001654954-25-009966
- form_type: 8-K
- ticker: CVM
- cik: 0000725363
- company_name: CEL SCI CORP
- filed_at: 2025-08-25T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/725363/000165495425009966/0001654954-25-009966-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/725363/000165495425009966/cvm_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-25-009966
- JSON: https://secwatch.observer/filing/0001654954-25-009966.json
- Plain text: https://secwatch.observer/filing/0001654954-25-009966.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.